INSM Insmed Incorporated

144.46USD+20.58%Mkt Cap: 31.69B USDP/E: —

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory …

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap31.69B USD
Enterprise Value25.87B USD
Revenue (TTM)1.52B USD
Gross Profit483.49M USD
Net Income (TTM)-1.28B USD
Revenue/Share7.02 USD
Last Price144.46 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.7K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)225.06
PEG1.09
EV/EBITDA-42.33
EV/Revenue17.02
P/S20.85
P/B43.63
EPS (TTM)-2.88 USD
EPS (Forward)0.66 USD
52W Range
90.3944% of range212.75
52W High212.75 USD
52W Low90.39 USD
Profitability
Gross Margin79.73%
Oper. Margin-41.66%
EBITDA Margin-40.21%
Profit Margin-210.54%
ROE-172.78%
ROA-56.38%
ROIC—
ROCE-55.40%
Growth
Revenue Growth268.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-935.01M USD
CapEx (TTM)32.56M USD
FCF Margin-30.06%
FCF Yield-1.44%
Net Debt-415.69M USD
Net Debt/EBITDA0.68
Net Debt/FCF—
Balance Sheet
Debt/Equity0.79
Current Ratio2.86
Quick Ratio2.36
Book Value/Sh3.31 USD
Cash/Share5.23 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 3, 2011
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)194.18 USD
Upside (mean)+34.4%
Target Range158.00 USD – 243.00 USD
158.00+34.4% to mean243.00
# Analysts22
Ownership
Shares Out.219.38M
Float217.93M
Insiders0.52%
Institutions104.01%
Short Interest
Short Ratio3.8d
Short % Float7.23%
Short % Out.6.42%
Shares Short14.08M
Short (prev mo.)13.80M
Technical
SMA 50110.75 (+30.4%)
SMA 200122.99 (+17.5%)
Beta0.81
S&P 52W Chg12.08%
Avg Vol (30d)3.70M
Avg Vol (10d)3.08M
Technical Indicators
RSI (14)77.4
MACD6.2709
MACD Signal3.5072
MACD Hist.+2.7637
BB Upper137.37 USD
BB Middle112.72 USD
BB Lower88.07 USD
BB Width43.74%
ATR (14)6.570 USD
Vol Ratio (20d)3.91x

About Insmed (NASDAQ: INSM)

›

Insmed (NASDAQ: INSM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,664 employees.

The shares were at 144.46 USD on 19 November 2026, down 22.2% over 52 weeks. Its 52-week range is 90.39 USD to 212.75 USD: the price is 32.1% below the high and 59.8% above the low.

Its market capitalisation is 31.69B USD.

Insmed reports return on equity of -172.8%, an operating margin of -41.7% and revenue up 268.4% year over year.

It holds more cash than debt, a net cash position of 415.69M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 22 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 194.18 USD is 34.4% above the current price. The next earnings report is expected on 18 February 2027.